Abstract

Apatinib, an inhibitor of vascular endothelial growth factor receptor-2, has been shown to promote anti-cancer action across a wide range of malignancies, including gastric, lung, and breast cancers. Our previous study showed that apatinib increases apoptosis in anaplastic thyroid carcinoma (ATC), but the direct functional mechanism of tumor lethality mediated by apatinib is still unknown. In this study, we demonstrated that apatinib induced both autophagy and apoptosis in human ATC cells through downregulation of p-AKT and p-mTOR signals via the AKT/mTOR pathway. Moreover, inhibition of apatinib-induced autophagy increased apatinib-induced apoptosis in ATC cells, and additional tumor suppression was critically produced by the combination of apatinib and the autophagy inhibitor chloroquine in vivo and in vitro. These findings showed that both autophagy and AKT/mTOR signals were engaged in ATC cell death evoked by apatinib. ATC patients might benefit from the new anti-cancer drug, and molecular targeted treatment in combination with autophagy inhibitors shows promise as a treatment improvement.

Highlights

  • Thyroid cancer is one of the most common malignant endocrine tumors

  • LC3 lipidation is a specific marker of autophagosomes in mammalian cells, and it is widely used in autophagy measurement

  • Our results showed that the expression of LC3-II (LC3 lipidation), Beclin 1 and ATG7 were parallel to the increase in apatinib concentration, whereas P62 was decreased (Fig. 2a, b)

Read more

Summary

Introduction

Thyroid cancer is one of the most common malignant endocrine tumors. More than 50,000 new thyroid cancer cases would be diagnosed in 2018, and the quantity of cases shows an obvious increasing trend[1]. A small-molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), can induce apoptosis and suppress tumor proliferation in a variety of tumors[5,6,7]. This drug has shown promising results in gastric cancer patients who failed standard chemotherapy[8,9]. Clinical trials that include breast cancer, esophageal cancer, colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC) are currently under investigation[10,11,12,13,14]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.